Person with PH1
*Alnylam is proud to feature real patients in our advertising. Patients may or may not be on an Alnylam therapy.
Alnylam Assist™ provides support services for your patients throughout treatment with OXLUMO® (lumasiran).
This program offers support services for patients being treated with OXLUMO. If you would like to access OXLUMO for one of your patients through Alnylam Assist™, the first step is completing the Start Form.
Alnylam Assist™ can help PH1 patients prescribed OXLUMO®:
Start treatment with OXLUMO.
Understand their benefits and coverage, as well as eligibility for financial assistance options such as the Commercial Copay Program.*†
Connect with Alnylam for ongoing information and product support.
Learn more about PH1 and treatment with OXLUMO.
An Alnylam Field Reimbursement Director can provide education about billing, coding, coverage, and reimbursement for OXLUMO.
Patients must meet specified eligibility criteria to qualify for assistance. Alnylam reserves the right to make eligibility determinations and to modify or discontinue the program at any time.
Patients with Medicare, Medicaid, or other government-sponsored insurance are not eligible for the Alnylam Assist™ Commercial Copay Program. Out-of-pocket costs for the administration of OXLUMO will not be covered for patients residing where it is prohibited by law or where otherwise restricted.
• Electronic Start Form
Fill out the Electronic Start Form online with your patient.
• Downloadable Start Form
Print the Start Form, complete it with your patient, then fax it to 1-833-256-2747.
• DocuSign Start Form
Begin the Start Form, then send it to your patient via email to complete their portion.
What happens next?
- An Alnylam Case Manager will reach out to you and your patient within 2 business days of receiving the completed Start Form.
- Alnylam Assist™ will help your patient access OXLUMO.
Alnylam Assist™ offers support services for your patients prescribed OXLUMO:
Benefits verification Help determining patient-specific coverage. Within 2 business days of receiving the Start Form, an Alnylam Case Manager will reach out to your patient to begin discussing their insurance benefits.
Financial assistance Alnylam is committed to making OXLUMO available to those who need it. When starting treatment, an Alnylam Case Manager will help determine eligibility for one of Alnylam's financial assistance programs.a
Alnylam Assist™ Patient Assistance Program (PAP): Provides OXLUMO at no cost to eligible patients, primarily the uninsured, who meet specified financial criteria.
Alnylam Assist™ Commercial Copay Programb: Covers certain out-of-pocket costs for eligible patients with commercial insurance.
Patient education Disease education and product information for patients and their families through trained Alnylam Patient Education Liaisons (PELs)
- The purpose of Alnylam Patient Education Liaisons (PELs) is to provide education to patients, their families, and caregivers
- PELs are employees of Alnylam Pharmaceuticals and do not provide medical advice
- All diagnosis and treatment decisions should be made by the treating physician and their patient
Field Reimbursement Directors Alnylam Field Reimbursement Directors are available to answer coverage, coding, and reimbursement-related questions about Alnylam products.
Tell Me More About Alnylam Assist™
Patients must meet specified eligibility criteria to qualify for assistance. Alnylam reserves the right to make eligibility determinations and to modify or discontinue the program at any time.
Patients with Medicare, Medicaid, or other government-sponsored insurance are not eligible for the Alnylam Assist™ Commercial Copay Program. Out-of-pocket costs for the administration of OXLUMO will not be covered for patients residing where it is prohibited by law or where otherwise restricted.
Downloadable patient brochure
A guide to help your patients better understand their condition and navigate treatment with OXLUMO.
Download the OXLUMO patient brochure for more information.
WANT TO SPEAK WITH AN OXLUMO REPRESENTATIVE?
Our representatives are available to provide detailed information about OXLUMO and how it may help your patients with PH1.
Patient advocacy organizations
Help your patient expand their network and stay informed by connecting them with independent patient advocacy organizations.
We hope you find the resources mentioned here helpful. Alnylam Pharmaceuticals is not affiliated with any of these organizations. By listing these resources, Alnylam Pharmaceuticals is not endorsing any particular service or group, and we are not responsible for the content of these sites or services. They are provided for informational purposes and should not replace a doctor’s medical advice.